Peptide Probes for Non-Invasive Amyloid Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective and non-invasive diagnostic tools for detecting misfolded protein aggregates associated with amyloidogenic diseases, such as Alzheimer's, in the eye, which could serve as a proxy for brain health.
Innovation Solution
Development of peptide or peptoid probes that preferentially associate with Aβ protein aggregates in the eye, generating a detectable signal upon binding, allowing for their detection in ocular tissues like the retina and optic nerve using retinal imaging devices.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic methods are used for detecting misfolded protein aggregates, then detection can be performed, but the methods are invasive and complex
Solution Approach 1:
The patent uses peptide probes as intermediary molecules that bind specifically to misfolded protein aggregates in ocular tissues. These probes serve as mediators between the target proteins and detection systems, enabling indirect but accurate detection through fluorescent labeling and imaging, thus achieving reliable detection without direct complex biochemical analysis
Solution Approach 2:
The patent replaces complex mechanical and biochemical diagnostic procedures with optical detection methods. By using fluorescently labeled peptide probes and retinal imaging devices, the system substitutes invasive tissue sampling and complex laboratory analysis with non-invasive light-based imaging, simplifying the diagnostic process while maintaining accuracy
2Reliability
If invasive diagnostic procedures are used to detect protein aggregates, then reliable detection is achieved, but patient safety and comfort deteriorate
Solution Approach 1:
The ocular tissues (retina, optic nerve, vitreous body) serve as intermediary structures that provide access to brain health information without directly sampling brain tissue. The peptide probes bind to protein aggregates in these accessible ocular structures, allowing indirect detection of brain pathology through safe and non-invasive ocular imaging
Solution Approach 2:
The patent uses the eye as a proxy or copy of brain health status. Since ocular tissues share similar protein composition and are accessible through non-invasive imaging, they provide a safe copy of brain pathology information, eliminating the need for risky brain tissue sampling while maintaining diagnostic reliability
3Measurement precision
If conventional detection methods are employed, then protein aggregates can be identified, but early stage detection capability is limited
Solution Approach 1:
The patent enables preliminary detection of protein aggregates in ocular tissues before they cause significant brain damage or clinical symptoms appear. By using sensitive peptide probes that bind to early-stage aggregates and non-invasive imaging, the system performs preliminary screening that can identify disease before it progresses, reducing diagnosis delay
Solution Approach 2:
The patent replaces insensitive conventional detection methods with highly sensitive fluorescent peptide probe-based imaging. This substitution enables detection of low-abundance early-stage aggregates through optical signals, significantly improving measurement precision and enabling earlier diagnosis compared to traditional methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early diagnosis and monitoring of amyloidogenic diseases by localizing and quantifying protein aggregates in the eye, providing a safe, low-cost, and non-invasive means for assessing disease progression and potential brain involvement.
Implementation Method 1
the probe undergoes a conformation change upon association with the protein aggregates
Implementation Method 2
the first and second labels are excimer-forming labels
Implementation Method 3
the first and second labels comprise pyrene or a fluorophore/quencher pair
Implementation Method 4
the first label comprises one member of a fluorescent resonance energy transfer (FRET) pair and the second label comprises the other member of the FRET pair
Data Source
AI summary
Described are methods for the detection, in the eye of an individual, of protein aggregates or other misfolded proteins associated with disease using peptide or peptide mimic probes that preferentially associate with the protein aggregates or misfolded proteins, which can be accomplished non-invasively.